REGULATORY

• MHLW Presents Plan to Expand Orphan Drug Designation by Clarifying Requirements
  July 11, 2023

• Boost PMDA Manpower to Respond to Proposed Orphan Revamp: Panelists
  July 11, 2023

• MHLW Proposes Simultaneous Preparation of Drug Development Plans for Adults and Children
  July 11, 2023

• MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
  July 11, 2023

• Label Expansions for Jakavi, Soliris Up for MHLW Panel Review on July 24
  July 11, 2023

• PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
  July 10, 2023

• Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
  July 7, 2023

• Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
  July 7, 2023

• Japan Appropriately Reviewing Alzheimer’s Med Lecanemab: Minister
  July 7, 2023

• Reflect Societal Values in Pricing of Regenerative Medicines: FIRM
  July 7, 2023

• JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
  July 6, 2023

• Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
  July 6, 2023

• Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
  July 6, 2023

• Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
  July 6, 2023

• Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
  July 6, 2023

• 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
  July 6, 2023

• Hideo Hashimoto Named MOF Budget Examiner for Healthcare
  July 5, 2023

• MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
  July 4, 2023

• MHLW Panel OKs 282 More Health Damage Claims for COVID Vaccines
  July 4, 2023

• Hiroyuki Uchiyama Tapped as Assistant Vice Minister for Pharma Promotion
  July 3, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 84
• 85
• 86
• 87
• 88
• 89
• 90
• 91
• 92
• …
• Next ›
• 最終 »